We recently revealed that BCL6 enables solid tumor cells to evade genotoxic stress (21), and pharmacological inhibition of BCL6 enhances the sensitivity of KRAS-mutant lung cancer cells to clinical BETi (22). This evidence concerns the gene BCL6 and lung carcinoma.